Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anebulo Pharmaceuticals, Inc. (ANEB)
USD0.34
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
1017 Ranch Road 620 South 78734
Lakeway, TX, US
Lakeway, TX, US
CEO
Richard Anthony Cunningham
Website
anebulo.com
IPO
2021-05-07
CIK 1815974 ISIN US0345691036
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.34
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3.9K
Beta
-1.87
Float Shares
24.13M
Free Float %
59.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.69% | -0.65% | -14.47% | -3.14% | -80.59% | -54.46% | -53.06% | -80.22% | -93.43% | -93.52% | -93.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
0.34
Low
6.00
+1,683.6%
Consensus
6.00
+1,683.6%
Median
6.00
+1,683.6%
High
6.00
+1,683.6%
DCF (Unlevered)
0.34
+0.9%
DCF (Levered)
0.34
+2.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
6.00
+1,683.6%
|
Quality scores
Altman Z-Score
-5.82
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+21.9% Q4'25: +45.8% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-26,938.2% Q4'25: +948.2% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+31.0% Q4'25: +49.9% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
|
16.83M
16.83M – 16.83M
|
27.31M
27.31M – 27.31M
+62.3% YoY
|
78.75M
78.75M – 78.75M
+188.4% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-8.10M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-8.10M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-8.48M
est: -9.64M (+12.0%)
|
-16.23M
-16.23M – -16.23M
-68.4% YoY
|
-15.56M
-15.56M – -15.56M
+4.2% YoY
|
-16.57M
-16.57M – -16.57M
-6.5% YoY
|
-18.26M
-18.26M – -18.26M
-10.2% YoY
|
| SGA |
4.92M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.25
est: -0.29 (+12.3%)
|
-0.48
-0.48 – -0.48
-68.4% YoY
|
-0.46
-0.46 – -0.46
+4.2% YoY
|
-0.49
-0.49 – -0.49
-6.5% YoY
|
-0.54
-0.54 – -0.54
-10.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
17
Total invested
22.43M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
17
-3 vs prev Q
New positions
1
Closed positions
4
Increased
6
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | 22NW, LP | 15.47M +— (+0.0%) | 84.76M +46.1M (+119.2%) | 37.65% -8.086 pp | 35.68% +17.459 pp | USD2.93 -65.5% | 19 qtrs — |
| 2 | NANTAHALA CAPITAL MANAGEMENT, LLC | 3.04M +— (+0.0%) | 3.07M -4.5M (-59.6%) | 7.39% -1.587 pp | 0.10% -0.162 pp | USD1.87 -46.0% | 14 qtrs — |
| 3 | MANGROVE PARTNERS | 2.53M +— (+0.0%) | 2.55M -3.8M (-59.6%) | 6.15% -1.320 pp | 0.21% -0.259 pp | USD1.68 -39.9% | 5 qtrs — |
| 4 | VANGUARD GROUP INC | 435.8K +129.3K (+42.2%) | 440.2K -326.2K (-42.6%) | 1.06% +0.154 pp | 0.00% +0.000 pp | USD1.87 -46.0% | 11 qtrs — |
| 5 | MORGAN STANLEY | 399.4K +— (+0.0%) | 403.4K -595.1K (-59.6%) | 0.97% -0.209 pp | 0.00% +0.000 pp | USD2.38 -57.6% | 9 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 160.8K -13.3K (-7.7%) | 162.5K -273.1K (-62.7%) | 0.39% -0.124 pp | 0.00% +0.000 pp | USD1.79 -43.6% | 8 qtrs — |
| 7 | RANGELEY CAPITAL, LLC | 50.0K +30.0K (+150.0%) | 50.5K +500.0 (+1.0%) | 0.12% +0.063 pp | 0.04% -0.001 pp | USD1.61 -37.3% | 2 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 25.1K -3.4K (-11.9%) | 25.3K -45.9K (-64.4%) | 0.06% -0.023 pp | 0.00% 0.000 pp | USD2.50 -59.6% | 2 qtrs — |
| 9 | CITADEL ADVISORS LLC | 24.2K +24.2K (+100.0%) | 24.5K +24.5K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD1.01 +0.0% | 4 qtrs — |
| 10 | BLACKROCK, INC. | 23.8K -270.0 (-1.1%) | 24.0K -36.1K (-60.1%) | 0.06% -0.013 pp | 0.00% +0.000 pp | USD1.81 -44.2% | 6 qtrs — |
| 11 | NORTHERN TRUST CORP | 22.0K -2.4K (-9.8%) | 22.2K -38.8K (-63.6%) | 0.05% -0.019 pp | 0.00% +0.000 pp | USD2.50 -59.6% | 2 qtrs — |
| 12 | IKARIAN CAPITAL, LLC | 17.7K -140.0K (-88.8%) | 17.9K -376.4K (-95.5%) | 0.04% -0.423 pp | 0.00% -0.038 pp | USD6.79 -85.1% | 19 qtrs — |
| 13 | STATE STREET CORP | 12.8K +— (+0.0%) | 12.9K -19.0K (-59.6%) | 0.03% -0.007 pp | 0.00% +0.000 pp | USD2.50 -59.6% | 2 qtrs — |
| 14 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.2K +1.5K (+84.6%) | 3.3K -1.1K (-25.4%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD2.07 -51.2% | 16 qtrs — |
| 15 | UBS GROUP AG | 2.3K +2.1K (+960.9%) | 2.4K +1.8K (+328.5%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD1.11 -9.0% | 8 qtrs — |
| 16 | JPMORGAN CHASE & CO | 2.3K +115.0 (+5.4%) | 2.3K -3.1K (-57.4%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD2.42 -58.3% | 8 qtrs — |
| 17 | BANK OF AMERICA CORP /DE/ | 382.00 -509.0 (-57.1%) | 386.00 -1.8K (-82.7%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.33 -24.1% | 9 qtrs — |
| 18 | BARCLAYS PLC | — -399.0 (-100.0%) | — -998.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 19 | CITIGROUP INC | — -6.0 (-100.0%) | — -15.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 20 | BOOTHBAY FUND MANAGEMENT, LLC | — -18.8K (-100.0%) | — -47.1K (-100.0%) | 0.00% -0.056 pp | 0.00% -0.001 pp | USD— | 19 qtrs SOLD |
| 21 | XTX TOPCO LTD | — -19.2K (-100.0%) | — -47.9K (-100.0%) | 0.00% -0.057 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
254.4K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+254,433
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-04 | SHAH BIMAL R. | Director | A-Award | A | Stock Option (right to buy) | 6,618 | 1.02 | 6.8K | 6,618 | D | ↗ |
| 2025-04-04 | Lin Kenneth | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | D | ↗ |
| 2025-04-04 | Lawler Joseph F. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | D | ↗ |
| 2025-04-04 | Kupchyk Areta | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | D | ↗ |
| 2025-04-04 | English Aron R. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 2,647 | 1.02 | 2.7K | 2,647 | D | ↗ |
| 2025-04-04 | Cunningham, Richard Anthony | Director / Officer | A-Award | A | Stock Option (right to buy) | 316,352 | 1.02 | 322.7K | 316,352 | D | ↗ |
| 2025-04-04 | Cundy Kenneth C | Officer | A-Award | A | Stock Option (right to buy) | 115,037 | 1.02 | 117.3K | 115,037 | D | ↗ |
| 2025-04-04 | Calloway Nathaniel | Director | A-Award | A | Stock Option (right to buy) | 3,309 | 1.02 | 3.4K | 3,309 | D | ↗ |
| 2025-04-04 | Aryeh Jason | Director | A-Award | A | Stock Option (right to buy) | 4,964 | 1.02 | 5.1K | 4,964 | D | ↗ |
| 2024-12-23 | English Aron R. | Director / 10% Owner | P-Purchase | A | Common Stock | 10,101,010 | 0.99 | 10.00M | 15,467,300 | I | ↗ |
| 2024-12-09 | Cunningham, Richard Anthony | Director / Officer | A-Award | A | Stock Option (right to buy) | 254,433 | 1.56 | 396.9K | 254,433 | D | ↗ |
| 2024-06-13 | SHAH BIMAL R. | Director | A-Award | A | Stock Option (right to buy) | 3,309 | 2.10 | 6.9K | 3,309 | — | ↗ |
| 2024-06-13 | Lin Kenneth | Director | A-Award | A | Stock Option (right to buy) | 41,667 | 2.10 | 87.5K | 41,667 | — | ↗ |
| 2024-06-13 | Lawler Joseph F. | Director | A-Award | A | Stock Option (right to buy) | 6,618 | 2.10 | 13.9K | 6,618 | — | ↗ |
| 2024-06-13 | Kupchyk Areta | Director | A-Award | A | Stock Option (right to buy) | 1,324 | 2.10 | 2.8K | 1,324 | — | ↗ |
| 2024-06-13 | English Aron R. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 41,667 | 2.10 | 87.5K | 41,667 | — | ↗ |
| 2024-06-13 | Calloway Nathaniel | Director | A-Award | A | Stock Option (right to buy) | 1,655 | 2.10 | 3.5K | 1,655 | — | ↗ |
| 2024-06-13 | Aryeh Jason | Director | A-Award | A | Stock Option (right to buy) | 2,482 | 2.10 | 5.2K | 2,482 | — | ↗ |
| 2024-02-29 | Cundy Kenneth C | Officer | A-Award | A | Stock Option (right to buy) | 72,613 | 2.72 | 197.5K | 72,613 | — | ↗ |
| 2023-12-18 | English Aron R. | Director / 10% Owner | G-Gift | A | Common Stock | 300,000 | 0.00 | — | 5,366,290 | — | ↗ |
| 2023-11-13 | English Aron R. | Director / 10% Owner | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2023-10-06 | SHAH BIMAL R. | Director | A-Award | A | Stock Option (right to buy) | 26,097 | 3.03 | 79.0K | 26,097 | — | ↗ |
| 2023-10-06 | Cunningham, Richard Anthony | Director / Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 3.03 | 1.82M | 600,000 | — | ↗ |
| 2023-09-28 | George Dan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-02 | GARDINER SANDRA A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-09 | Cundy Kenneth C | Officer | A-Award | A | Stock Option (right to buy) | 35,017 | 0.00 | — | 35,017 | — | ↗ |
| 2022-12-09 | ALLEN SIMON | Officer | A-Award | A | Stock Option (right to buy) | 70,246 | 0.00 | — | 70,246 | — | ↗ |
| 2022-11-01 | Calloway Nathaniel | Director | A-Award | A | Stock Option (right to buy) | 59,149 | 0.00 | — | 59,149 | — | ↗ |
| 2022-10-28 | Calloway Nathaniel | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-06-27 | ALLEN SIMON | Officer | A-Award | A | Stock Option (right to buy) | 77,457 | 0.00 | — | 77,457 | — | ↗ |
| 2022-06-01 | Cundy Kenneth C | Officer | A-Award | A | Option to purchase Common Stock | 350,169 | 0.00 | — | 350,169 | — | ↗ |
| 2022-05-20 | Cundy Kenneth C | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-21 | Parschauer Karah Herdman | Director | A-Award | A | Stock Option (right to buy) | 30,425 | 0.00 | — | 30,425 | — | ↗ |
| 2022-04-21 | Lin Kenneth | Director | A-Award | A | Stock Option (right to buy) | 30,425 | 0.00 | — | 30,425 | — | ↗ |
| 2022-04-21 | Lawler Joseph F. | Director | A-Award | A | Stock Option (right to buy) | 30,425 | 0.00 | — | 30,425 | — | ↗ |
| 2022-04-21 | Kupchyk Areta | Director | A-Award | A | Stock Option (right to buy) | 30,425 | 0.00 | — | 30,425 | — | ↗ |
| 2022-04-21 | Aryeh Jason | Director | A-Award | A | Stock Option (right to buy) | 30,425 | 0.00 | — | 30,425 | — | ↗ |
| 2022-04-21 | 22NW Fund, LP | Director | A-Award | A | Common Stock Purchase Warrant (right to buy) | 1,703,577 | 0.13 | 212.9K | 1,703,577 | — | ↗ |
| 2022-02-07 | ALLEN SIMON | Officer | A-Award | A | Option to purchase Common Stock | 625,000 | 6.15 | 3.84M | 625,000 | — | ↗ |
| 2022-02-01 | ALLEN SIMON | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-17 | English Aron R. | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 400 | 6.59 | 2.6K | 3,362,713 | — | ↗ |
| 2021-12-14 | English Aron R. | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 412 | 5.90 | 2.4K | 3,362,313 | — | ↗ |
| 2021-12-03 | English Aron R. | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 4,500 | 5.93 | 26.7K | 3,361,901 | — | ↗ |
| 2021-12-02 | English Aron R. | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 13,836 | 5.30 | 73.3K | 3,357,401 | — | ↗ |
| 2021-05-06 | Schneeberger Daniel | Officer | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 982,500 | — | ↗ |
| 2021-05-06 | Parschauer Karah Herdman | Director | — | D | Options to purchase Common Stock | 82,290 | 2.18 | 179.4K | 0 | — | ↗ |
| 2021-05-06 | Merchant James R. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-06 | Lin Kenneth | Director | — | D | Options to purchase Common Stock | 82,290 | 2.18 | 179.4K | 0 | — | ↗ |
| 2021-05-06 | Lawler Joseph F. | Director | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 12,000,000 | — | ↗ |
| 2021-05-06 | Kupchyk Areta | Director | — | D | Options to purchase Common Stock | 82,290 | 2.18 | 179.4K | 0 | — | ↗ |
| 2021-05-06 | English Aron R. | Director / 10% Owner | — | D | Options to purchase Common Stock | 82,290 | 2.18 | 179.4K | 0 | — | ↗ |
| 2021-05-06 | Aryeh Jason | Director | — | D | Options to purchase Common Stock | 82,290 | 2.18 | 179.4K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
40.78M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Richard Anthony Cunningham Chief Executive Officer | 332.9K | — | — | 1.37M | — | — | 1.70M | 80.42% | ↗ |
| 2 | 2024 | Kenneth C. Cundy Chief Scientific Officer | 380.8K | 112.0K | — | 119.4K | — | — | 612.2K | 19.50% | ↗ |
| 3 | 2024 | Simon Allen Former President and Chief Executive Officer | 131.4K | — | — | — | — | 385.4K | 516.8K | 0.00% | ↗ |
| 4 | 2024 | Daniel George Part time Chief Financial Officer | 147.3K | — | — | — | — | — | 147.3K | 0.00% | ↗ |
| 5 | 2023 | Simon Allen Former President and Chief Executive Officer | 472.6K | 164.1K | — | 141.4K | — | — | 778.0K | 18.17% | ↗ |
| 6 | 2023 | Kenneth C. Cundy Chief Scientific Officer | 361.7K | 63.5K | — | 70.5K | — | — | 495.6K | 14.22% | ↗ |
| 7 | 2023 | Rex Merchant Former Chief Financial Officer | 299.0K | — | — | — | — | — | 299.0K | 0.00% | ↗ |
| 8 | 2023 | Sandra A. Gardiner Former Acting Chief Financial Officer | — | — | — | — | — | 246.0K | 246.0K | 0.00% | ↗ |
| 9 | 2022 | Simon Allen President and Chief Executive Officer | 187.5K | — | — | 1.93M | — | — | 2.12M | 91.16% | ↗ |
| 10 | 2022 | Kenneth C. Cundy Chief Scientific Officer | 39.9K | — | — | 450.4K | — | — | 490.4K | 91.86% | ↗ |
| 11 | 2022 | Rex Merchant Chief Financial Officer | 275.0K | — | — | — | — | — | 275.0K | 0.00% | ↗ |
| 12 | 2022 | Daniel Schneeberger Former President and Chief Executive Officer | 8.8K | — | — | — | — | — | 8.8K | 0.00% | ↗ |
| 13 | 2021 | Daniel Schneeberger Former President and Chief Executive Officer | 14.0K | — | 106.4K | — | — | — | 120.4K | 88.39% | ↗ |
| 14 | 2021 | Daniel Schneeberger Chief Executive Officer and director | 14.0K | — | 106.4K | — | — | — | 120.4K | 88.39% | ↗ |
| 15 | 2021 | Rex Merchant Chief Financial Officer | 119.8K | — | — | — | — | — | 119.8K | 0.00% | ↗ |
| 16 | 2020 | Rex Merchant Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 17 | 2020 | Daniel Schneeberger Chief Executive Officer and director | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kenneth C. Cundy | Chief Scientific Officer | 512.5K | — |
| Richard Cunningham | Chief Executive Officer & Director | 461.3K | male |
| Daniel V. George | Acting Chief Financial Officer & Secretary | 208.8K | male |
| Joseph F. Lawler | Founder & Chairman | 11.0K | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANEB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
